Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rafael Holdings, Inc. (RFL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: RFL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.14% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.27M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.92 | 52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 |
52 Weeks Range 1.27 - 3.19 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1633.43% |
Management Effectiveness
Return on Assets (TTM) -9.82% | Return on Equity (TTM) -26.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21022811 | Price to Sales(TTM) 79.6 |
Enterprise Value 21022811 | Price to Sales(TTM) 79.6 | ||
Enterprise Value to Revenue 28.72 | Enterprise Value to EBITDA 5.39 | Shares Outstanding 34303200 | Shares Floating 15495922 |
Shares Outstanding 34303200 | Shares Floating 15495922 | ||
Percent Insiders 54.74 | Percent Institutions 9.37 |
Upturn AI SWOT
Rafael Holdings, Inc.
Company Overview
History and Background
Rafael Holdings, Inc., founded in 1973, originally focused on real estate. Over time, it transitioned into a holding company with investments primarily in pharmaceutical assets, particularly through its investment in Rafael Pharmaceuticals.
Core Business Areas
- Pharmaceutical Development: Focused on the development of cancer therapeutics through its majority ownership in Rafael Pharmaceuticals. Main product is devimistat.
- Real Estate: Previously a significant portion of the business, the real estate holdings have decreased focus as the company focuses on pharmaceutical developement.
Leadership and Structure
Aiman Shalabi serves as the CEO. The organizational structure includes a board of directors and management team overseeing both the pharmaceutical and real estate operations.
Top Products and Market Share
Key Offerings
- Devimistat: A clinical-stage compound being developed by Rafael Pharmaceuticals for the treatment of various cancers. No market share yet, as still in clinical trials. Competitors include companies with approved cancer therapeutics in the targeted indications, such as Pfizer, Novartis and Merck.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, characterized by stringent regulatory requirements and long development timelines. Cancer therapeutics is a major segment, with significant growth potential but also high risk.
Positioning
Rafael Holdings is a small player in the pharmaceutical industry, focused on developing novel cancer therapies. Its competitive advantage lies in its specific technology and intellectual property related to devimistat.
Total Addressable Market (TAM)
The global cancer therapeutics market is estimated to be worth billions of dollars. Rafael Holdings' devimistat, if approved, could address a portion of this TAM, depending on its efficacy and target indications.
Upturn SWOT Analysis
Strengths
- Novel cancer therapeutic in development (devimistat)
- Experienced management team
- Potential for breakthrough therapy designation
Weaknesses
- Reliance on a single clinical-stage asset
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Lack of revenue generation
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Breakthrough Therapy Designation and fast track approval
- Expansion to new cancer indications
Threats
- Clinical trial failure
- Regulatory hurdles
- Competition from established cancer therapies
- Patent expiration
- Inability to raise additional capital
Competitors and Market Share
Key Competitors
- PFE
- NVS
- MRK
- BMY
- AZN
Competitive Landscape
Rafael Holdings faces intense competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. They operate in a very competitive market for pharmaceutical research.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on clinical development and lack of product revenue.
Future Projections: Future growth is dependent on the successful commercialization of devimistat. Analyst projections vary widely based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing devimistat through clinical trials and securing partnerships to support development.
Summary
Rafael Holdings is a high-risk, high-reward investment opportunity centered on the development of devimistat. Its success hinges on positive clinical trial results and securing partnerships. The company has limited resources compared to its competitors and faces significant regulatory and commercialization hurdles, but if devimistat succeeds it could be a major win. It is a developmental stage pharmaceutical company that needs to raise more funding.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Rafael Holdings SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share estimates are approximations based on available data and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rafael Holdings, Inc.
Exchange NYSE | Headquaters Newark, NJ, United States | ||
IPO Launch date 2018-03-26 | CEO, Founder & Executive Chairman Mr. Howard S. Jonas | ||
Sector Real Estate | Industry Real Estate Services | Full time employees 28 | Website https://www.rafaelholdings.com |
Full time employees 28 | Website https://www.rafaelholdings.com | ||
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.